Skip to main content
OpenTrials
Completed

NCT Number: NCT01107249

A Trial of Esophageal and Gastric Stenting for Leak or Perforation

Long term follow-up of patients treated for esophageal fistulas with a newer occlusive self-expanding covered metal stents compared to traditional stents.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

The Methodist Hospital

Houston, Texas, 77030, United States

About this study

This study is written to evaluate our experience treating esophageal fistulas with occlusive self-expanding covered metal stents. The long-term outcomes of patients treated with this new type of stent are as yet unknown. The differences between these stents is also unknown, as well as the ease of removal, efficacy, and/or placement. The intent of this study is not to determine which stent is better, but to merely evaluate the use of both. With this in mind, there will be no randomization of stent use, nor will there be restrictions on which stent may be used in which setting. This will be left to the judgment of the clinical placing the stent.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must have radiographic or endoscopic proof of an esophageal leak or fistula.
  • Patients will be required to undergo imaging with CT scan, endoscopy, or fluoroscopy to investigate the leak. Once the location of the leak is identified, then patients must be taken for stenting and any adjunctive treatment within 12 hours of diagnosis or within 12 hours of arrival to The Methodist Hospital.
  • Patients must sign informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of the hospital.

Exclusion criteria

  • Patients who will not agree to return for routine follow-up and studies.
  • Patients who will not tolerate an endobronchial ultrasound or endoscopic procedure (coagulopathy [INR>1.8, PTT>60, or platelet level <50], hemodynamically unstable [MAP<50 or SBP<80], or other medical illness precluding safe endoscopy).
  • Patients who have a perforation too high to stent (such as the back of the pharynx, where a stent is not able to be placed), the only unfavorable anatomic location is this one listed above; we believe all other locations are amenable to stent placement.
  • Resectable carcinoma, megaesophagus, severe stricture, or caustic ingestion.

Treatment and study plan

Boston Scientific Ultraflex or Wallstent stents

Device

Stent used to maintain luminal patency in esophageal strictures and occlude esophageal fistulas to reduce gastric leaks, perforations and/or fistulas.

Other names: Ultraflex, ULTRAFLEX ESOPHAGEAL NG STENT SYSTEM

Primary outcomes

  1. Safety of esophageal stenting by conducting an Omnipaque swallow and by the success of leakage stops and fistula healing.

    Time frame: 15 - 30 days

    By results from all procedures as reported by the surgeon conducting the stenting in relationship to difficulty and/or complications, as well as patient tolerability. When the esophagus can be sealed and any contamination drained, the stents have successfully provided coverage to allow healing of the esophageal wall.

  2. Efficacy of esophageal stenting by the success of leakage stops and fistula healing.

    Time frame: 15 - 30 days

    By results from all procedures as reported by the surgeon conducting the stenting in relationship to difficulty and/or complications, as well as patient tolerability. When the esophagus can be sealed and any contamination drained, the stents have successfully provided coverage to allow healing of the esophageal wall.

  3. A 30 day duration of stent placement and the relation to the healing esophagus

    Time frame: 30 days

    By results from all procedures as reported by the surgeon conducting the stenting in relationship to difficulty and/or complications, as well as patient tolerability. Evaluation of the healing process of the esophagus within first 30 days with the capability of its removal procedure. When the esophagus can be sealed and any contamination drained, the stents have successfully provided coverage to allow healing of the esophageal wall.

Secondary outcomes

  1. An institutional protocol for stent management

    Time frame: 1 year

    Results will be considered for assessing and instituting an institutional protocol to become the standard of care for future patient situations.

Sponsors and collaborators

Lead sponsor

The Methodist Hospital Research Institute

Other

Registry information

Official study title

A Phase II Trial of Esophageal and Gastric Stenting for Leak or Perforation

Acronym: ESO-stent

Important dates

Study start
2010
Primary completion
2014
Study completion
2014
First posted
Apr 20, 2010
Registry last updated
Mar 17, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.